Form 4: Plus Therapeutics Director Clowes Acquires Shares and Warrants

Director Howard Clowes reports acquisition of Plus Therapeutics common stock and warrants.

Summary

• On May 8, 2024, Howard Clowes, a director of Plus Therapeutics, Inc., acquired 9,804 shares of common stock at a price of $2.04 per share.
• Following this transaction, Clowes directly owns 21,497 shares of common stock.
• Clowes also acquired 19,608 warrants with an exercise price of $1.79.
• Half of the warrants (9,804) expire on May 8, 2029 (Series A), while the other half (Series B) expire one year after the effectiveness of a registration statement covering the resale of the underlying common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard SEC filing reporting insider transactions. The acquisition of shares and warrants could be seen as a positive signal, but without further context, it's difficult to assess the overall impact.

Industry Context

This filing reflects insider activity, which is closely monitored by investors for signals about management's confidence in the company's prospects. It is a routine filing required by the SEC.

Stakeholder Impact

• The acquisition of shares and warrants by a director could be viewed positively by shareholders, potentially signaling confidence in the company's future performance.

Key Dates

Keywords

Form 4, Beneficial Ownership, Director, Howard Clowes, Plus Therapeutics, PSTV, Common Stock, Warrants, Acquisition